More than 28 million people worldwide are living with heart valve disease, and the numbers are climbing. In the U.S., the ...
Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback